FDA Committee OK\'s Moderna mRNA-1010 Influenza Shot with Less Than 1% Absolute Benefit, Clears the Way for FDA Approval
VRBPAC members revealed: a former Moderna advisory board member, current GlaxoSmithKline and Merck executives, federal and university figures whose careers depend on vaccines.
Jon Fleetwood
Jun 19, 2026
The advisory committee nevertheless voted 9-0 in favor of the vaccine for adults aged 50 to 64 and 9-0 in favor of the vaccine for adults 65 and older.